GSK Acquired Wave Life Sciences Hepatic Program
The pharmaceutical giant paid $12 million to expand its siRNA-based portfolio in the hepatology space.
Updated on Sept. 30, 2026 in Biotech
Live Poll
Do you believe collaborative pharmaceutical partnerships ultimately benefit patients through lower drug prices?
GSK has acquired a new hepatic program from Wave Life Sciences, marking a $12 million upfront investment. The move is part of the companys ongoing strategy to develop drugs using small interfering RNA technology.
Why it matters
GSK is looking to bolster its hepatology-focused siRNA drug portfolio. By securing this program, the company aims to leverage specialized design platforms to develop new treatments for liver-related conditions.
GSK paid an upfront $12 million for the program, which is eligible for up to $375 million in milestone payments. This follows a 2022 collaboration involving $170 million for options to advance eight separate programs.
The players
GSK
GSK is a major global pharmaceutical company focused on the research, development, and manufacture of medicines and vaccines.
Wave Life Sciences
Wave Life Sciences is a biotechnology company that specializes in the development of genetic medicines using RNA-targeted therapies.
The details
The acquired candidate utilizes Wave Life Sciences' PRISM platform and SpiNA design to address liver-focused health targets. This acquisition operates under the terms of a 2022 collaboration agreement between the two firms.
Timeline
The initial collaboration agreement between GSK and Wave Life Sciences was signed in 2022.
By January 2026, GSK had selected four programs for development.
GSK returned the rights for a separate RNA editing candidate in February 2026.
The acquisition of the new hepatic program was announced on September 30, 2026.
The Big Picture
This acquisition continues the development roadmap established by the GSK and Wave Life Sciences 2022 collaboration agreement. It highlights the industry-wide push for firms to secure specific RNA-based assets to stay competitive in the hepatology sector.
This move signals a long-term commitment to developing siRNA-based treatments, which may eventually lead to new therapeutic options for patients with liver conditions. Investors should note that the success of this program depends on hitting future developmental milestones.
The takeaway
The acquisition demonstrates how major pharmaceutical companies use multi-year collaboration agreements to systematically build their pipeline of specialized genetic therapies. This modular approach allows firms to selectively acquire and develop promising drug candidates while mitigating risks.
What happens next
Wave Life Sciences is currently moving three additional programs toward candidate selection under the ongoing terms of their collaborative research arrangement with GSK.
Further reading
Learn more about the latest industry developments in the Biotech sector.
Live Poll
Do you believe collaborative pharmaceutical partnerships ultimately benefit patients through lower drug prices?
